{"schema_version":"secwatch.filing_event.v1","accession":"0001420720-25-000001","form_type":"8-K","ticker":"IBIO","cik":"0001420720","company_name":"iBio, Inc.","filed_at":"2025-01-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.586459+00:00","generated_at":"2026-05-28T18:01:36.396854+00:00","sec_items":["1.01","3.02","7.01","9.01"],"event_type":"m_and_a","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"iBio licenses anti-myostatin antibody IBIO-600 from AstralBio; launches bispecific program for obesity","bullets":["Upfront payment of $750,000 paid in common stock; milestones up to $28M.","IBIO-600 is a long-acting anti-myostatin antibody designed for subcutaneous use.","iBio initiated a bispecific antibody program targeting myostatin/activin A for obesity and cardiometabolic disorders.","Preclinical studies show potent myostatin inhibition; NHP data expected early 2025.","Plans to enter clinical trials in obesity and cardiometabolic disorders in 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001420720-25-000001","json":"https://secwatch.observer/filing/0001420720-25-000001.json","markdown":"https://secwatch.observer/filing/0001420720-25-000001.md","text":"https://secwatch.observer/filing/0001420720-25-000001.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000001/0001420720-25-000001-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1420720/000142072025000001/ibio-20241230x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T18:01:36.396854+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}